Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK delivers Q1 sales of £7.4 billion -18% AER, -15% CER Total EPS 21.5p, -32% AER, -25% CER; Adjusted EPS 22.9p -39% AER, -33% CER
Q1 performance reflects expected year-on-year impact and disruption from COVID-19
-
European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer
The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe.
-
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
-
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19.
-
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
-
GSK announces Dr Anne Beal to join the Board as Non-Executive Director
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne Beal will join the Board of the Company as a Non-Executive Director.
-
GSK to support manufacture of Novavax’ COVID-19 vaccine
GSK to support manufacture of up to 60 million doses of Novavax’ COVID-19 vaccine.
-
Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19
In combination, the 2 monoclonal antibodies demonstrated 70% relative reduction in persistent high viral load at day 7 compared to placebo.
-
GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19
The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE trial.
-
GSK receives CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis
This CHMP opinion follows the recent label expansion by the US FDA to include lupus nephritis
-
Moncef Slaoui Departs Galvani Bioelectronics Board of Directors
Moncef Slaoui has been terminated as Chair of the Galvani Board of Directors, effective immediately.
-
Half of parents surveyed either cancelled or delayed their child’s scheduled meningitis vaccination during the COVID-19 pandemic – GSK survey shows [1]
The Ipsos survey on behalf of GSK offers insight into the pandemic's impact on meningitis vaccinations over the last 12 months.
-
GSK to highlight scientific research in ovarian and endometrial cancer at SGO 2021 Annual Meeting on Women’s Cancer
This research builds on the body of evidence supporting poly (ADP-ribose) polymerase (PARP) inhibitor use for maintenance treatment.
-
Back to the dentist – new study highlights urgent need to tackle oral healthcare habits post COVID-19
Due to restrictions and aims to reduce COVID-19 transmission, 30% of respondents had visited a dentist less frequently during the pandemic.
-
GSK starts the first phase 3 study with a long-acting anti-IL-5 treatment for patients with severe asthma
GSK '294 is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Medicago/GSK announce Ph 3 trial start of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant.
-
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
-
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.
-
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks
Long-term efficacy and safety data from phase IIIb ATLAS-2M study reinforce therapeutic potential of long-acting cabotegravir & rilpivirine
-
GSK makes landmark pricing agreement for rotavirus vaccine, Rotarix, for use with children living in humanitarian crises
GSK has committed to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism.
